pyridoxamine has been researched along with metformin in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Audic, N; Ermolenko, L; Franck, G; Garcia-Alvarez, MC; Martin, MT; Nhiri, N; Potier, P; Sasaki, NA; Wang, Q | 1 |
Barter, PJ; Brown, BE; Davies, MJ; Nobécourt, E; Rye, KA; Yadav, S; Zeng, J | 1 |
Ahmad, S; Baig, MH; Khan, MS; Saeed, M; Shahab, U; Srivastava, AK | 1 |
3 other study(ies) available for pyridoxamine and metformin
Article | Year |
---|---|
N-Terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE) formation.
Topics: beta-Alanine; Chromatography, High Pressure Liquid; Electrophoresis, Polyacrylamide Gel; Glycation End Products, Advanced; Magnetic Resonance Spectroscopy; Peptides; Pyruvaldehyde | 2009 |
Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I.
Topics: Apolipoprotein A-I; Arginine; Cross-Linking Reagents; Glycosylation; Guanidines; Humans; Lipoproteins, HDL; Lysine; Metformin; Phosphatidylcholine-Sterol O-Acyltransferase; Pyridoxamine; Pyruvaldehyde; Thiazoles; Tryptophan | 2008 |
Inhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation end-products.
Topics: Glycation End Products, Advanced; Glycosylation; Humans; Metformin; Pyridoxamine | 2013 |